- NeuroMab™ Anti-GARP Antibody,Clone NR3348P (Cat#: NRP-0422-P1639)
- NeuroMab™ Anti-EPHB2 Antibody,Clone NR1370P (Cat#: NRP-0422-P1220)
- NeuroMab™ Anti-FGFR1 Antibody,Clone NR3547P (Cat#: NRP-0422-P1244)
- NeuroMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- NeuroMab™ Anti-F-Spondin/SPON1 Antibody, Clone N24875P (CBP11839) (Cat#: NRZP-0822-ZP4740)
- NeuroMab™ Anti-Tau Antibody,Clone NR1808P (Cat#: NRP-0422-P2293)
- NeuroMab™ Anti-Tau Antibody,Clone NR2218P (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-SEZ6 Antibody, Clone NR30P (Cat#: NRP-0422-P517)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody,Clone NR2660P (Cat#: NRP-0422-P867)
- NeuroMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-40), Aggregation Kit, TTF Assay (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2/9-hEF1a-DIO-mCherry-P2A-TetTox-WPRE-pA (Cat#: NTA-2012-ZP268)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- AAV2/2Retro-CAG-DIO-EGFP-2A-TetTox-pA [Neural Tracing] (Cat#: NTA-2012-ZP303)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- ABCA1 Antisense Oligonucleotide (AK311445) (Cat#: NV-2106-P27)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein, cTfRMAb-GDNF (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-ASA BBB Shuttle Protein, HIRMab-ASA (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, cTfRMAb-IDUA (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-EPO BBB Shuttle Protein, HIRMab-EPO (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, HIRMab-IDUA (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, HIRMab-TNFR (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDS BBB Shuttle Protein, HIRMab-IDS (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein, cTfRMAb-EPO (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, cTfRMAb-TNFR (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein, HIRMab-GDNF (Cat#: NRZP-0423-ZP509)
Muscular Dystrophies Drug Discovery Service
Creative Biolabs has a comprehensive technology platform and deep project experience for neuroscience research. We work closely with our clients to develop cutting-edge disease research. We provide a variety of services to support disease research needs.
Overview
Muscular dystrophies refer to a group of inherited disorders characterized by progressive muscle weakness, wasting, and degeneration. Amongst these, Duchenne muscular dystrophy (DMD) is the most severe and common form. Currently, there is no effective treatment to stop the progression of the deadly disease, although several promising experimental strategies are currently being investigated.
Fig.1 The muscular dystrophies and organization of the dystrophin-glycoprotein complex. (Khurana, 2003)
Creative Biolabs' Molecular Mechanisms Research of Muscular Dystrophies
Genetically, MDs can be inherited in a dominant or recessive manner or, in many cases, caused by de novo mutations, which are therefore sporadic. Studies of muscle cells in muscular dystrophy have shown that mutated proteins cause perturbations of many cellular components. MDs have been associated with mutations in structural proteins, signaling molecules, and enzymes as well as mutations that result in aberrant processing of mRNA or alterations in post-translational modifications of proteins. These findings not only reveal important insights from cell biologists but also offer unexpected and exciting new approaches to therapy.
Creative Biolabs' Animal Models of Muscular Dystrophy
To explore therapeutic approaches, animal models are needed, and these should mimic human disorders. An obvious challenge in studying MDs is the heterogeneity of these diseases. This has led to the development of several animal models that are used experimentally to study some of the MDs. The most widely used experimental animal model of DMD is the mdx mouse. There are also models of muscular dystrophy in other species, such as dogs that lack dystrophin (CXMD dog) and the cardiomyopathic hamster, which lacks σ-sarcoglycan. Animal studies have used methods such as running, swimming, and electrical stimulation to determine the effects of training on animals with muscular dystrophy.
Present Therapeutics
Present therapeutic strategies can be broadly divided into three groups: gene therapy approaches; cell therapy; and pharmacological therapy. Gene- and cell-based therapies offer the fundamental advantage of not having to correct secondary defects/pathologies (e.g., contractures) alone, especially if the treatment is started early in the disease. Gene therapy strategies attempt to deliver coding regions of the gene encoding dystrophin using specialized delivery vehicles (vectors). Cell-based strategies attempt to transplant muscle precursors such as myoblasts or stem cells taken from healthy donors, into dystrophin-deficient muscle.
Creative Biolabs' One-stop Shop Services for Muscular Dystrophy Preclinical Drug Discovery
- In Vitro Services
- In Vivo Services
- Ex Vivo Services
- Discovery Services
- Development Services
Creative Biolabs prides itself on maintaining long-term relationships with its clients. By listening, discussing, and understanding your needs, we determine the solution that best fits your needs. As your partner, you can rely on our team of experts to assist in your disease research to advance your project. Please feel free to contact us for your Muscular Dystrophy research project.
Reference
- Khurana, T.S.; Davies, K.E. Pharmacological strategies for muscular dystrophy. Nature Reviews Drug Discovery. 2003, 2(5): 379-390.